Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11581853 | 1.00 | MME (0.56) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL497336 | 1.00 | MME (0.56) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| Hydrochloric Acid SCHEMBL1027766 | 0.98 | MME (0.54) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| Hydrochloric Acid SCHEMBL7362927 | 0.98 | MME (0.54) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL17915462 | 0.93 | MME (0.61) | MMEALDH1A1MMP2MMP9 | |
| SCHEMBL121370 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| SCHEMBL121371 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| Benzophenone SCHEMBL9490253 | 0.92 | MEP1B (0.55) | MMEALDH1A1NPSR1MEP1BPSMB5 | |
| SCHEMBL11346818 | 0.92 | MME (0.58) | MMEALDH1A1PSMB5NAALAD2FOLH1 | |
| Benzophenone SCHEMBL9490249 | 0.92 | MEP1B (0.55) | MMEALDH1A1NPSR1MEP1BPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 772 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114533890-A | Preparation method and product of sorafenib liver cancer targeting micelle | 平顶山学院 | 2022-05-27 | — | — | CN | claimed |
| EP-2413711-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | Evonik Degussa GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2011147881-A2 | CYCLIC DIPEPTIDES AS FEEDSTUFF ADDITIVES | EVONIK DEGUSSA GMBH (DE) | 2011-12-01 | — | — | WO | claimed |
| WO-2010112365-A1 | DIPEPTIDE AS FEEDSTUFF ADDITIVE | EVONIK DEGUSSA GMBH (DE) | 2010-10-07 | — | — | WO | claimed |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | TOPO TARGET A/S (DK) | 2010-02-04 | — | — | US | claimed |
| EP-1689426-B1 | PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF INTERFERONS AND THERAPEUTIC APPLICATIONS THEREOF | FLAMEL TECH SA (FR) | 2009-12-30 | — | — | EP | claimed |
| EP-1689425-B1 | PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES AND THERAPEUTIC APPLICATIONS THEREOF | FLAMEL TECHNOLOGIE SA (FR) | 2009-12-09 | — | — | EP | claimed |
| EP-1567578-B1 | POLYAMINO ACIDS FUNCTIONALIZED BY AT LEAST ONE (OLIGO)AMINO ACID GROUP AND THERAPEUTIC USES | FLAMEL TECH SA (FR) | 2008-06-25 | — | — | EP | claimed |
| US-20070010652-A1 | Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications | STEPHANIE ANGOT, OLIVIER BREYNE, AND YOU-PING CHAN | 2007-01-11 | — | — | US | claimed |
| EP-1017358-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2004-08-11 | — | — | EP | claimed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | MME 4621/4885ALDH1A1 4294/4885NPSR1 3586/4885 |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | IDO1, IDO2, TDO2 | MME 2585/4885ALDH1A1 167/4885NPSR1 1053/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | MME 4709/4885ALDH1A1 4336/4885NPSR1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.